Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX

number of downloads : ?

Use this link to cite this item : https://ir.lib.shimane-u.ac.jp/53627

language	eng
Author	Harvey N. C. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, UK Kanis J. A. Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK Oden A. Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK Nakamura T. National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan Shiraki M. Research Institute and Practice for Involutional Diseases, 1610-1 Meisei, Misato, Azumino, Nagano, 399-8101, Japan Sugimoto, Toshitsugu Kuroda T. Medical Affairs Dept., Asahi-Kasei Pharma Corporation, 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo, 101-8101, Japan Johansson H. Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK McCloskey E. V. Centre for Metabolic Bone Diseases, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
Subject	Epidemiology; FRAX; Osteoporosis; Randomised controlled trial; Teriparatide; Vertebral fracture
Journal Title	OSTEOPOROSIS INTERNATIONAL
Volume	26
Issue	9
Start Page	2347
End Page	2353
ISSN	0937-941X
ISSN（Online）	1433-2965
Published Date	2015-09
DOI	10.1007/s00198-015-3129-7
PubMed ID	26092062
Publisher	SPRINGER LONDON LTD
NII Type	Journal Article
OAI-PMH Set	Faculty of Medicine
Remark	NH has received consultancy, lecture fees, and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare, and Internis Pharma. JA Kanis has received consulting fees, advisory board fees, lecture fees, and/or grant support from the majority of companies concerned with skeletal metabolism. EVM has received consultancy, lecture fees, research grant support, and/or honoraria from ActiveSignal, Alliance for Better Bone Health, AMGEN, Bayer, Consilient Healthcare, GE Lunar, Hologic, Internis Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Servier, Tethys, UCB, and Univadis. TN received research grants and/or consulting fees from Chugai Pharmaceutical, Teijin Pharma, Asahi Kasei Pharma, and Daiichi Sankyo. MS received consulting fees from Chugai, Daiichi Sankyo, Asahi Kasei Pharma, Teijin Pharma, and MSD. TS received consulting fee and/or research grant from Asahi-Kasei Pharma, Daiichi-Sankyo-Co., Eli Lilly Japan, and Pfizer. TK is an employee of Asahi Kasei Pharma Corporation. Anders Oden and Helena Johansson declare that they have no conflict of interest.